论文部分内容阅读
目的:评估炎症评分对接受放化疗(CRT)的局部晚期胰腺癌患者的无进展生存期(PFS)和总生存期(OS)的预测价值。方法:选取235例晚期胰腺癌患者,接受治疗前,所有患者均进行临床评估、实验室检查和影像学检查。比较两组患者的PFS和OS;评估与患者预后差、肿瘤减少率、6个月内肿瘤转移相关的预测因子。结果:患者平均PFS和OS分别为10.2个月和18.8个月。格拉斯哥预后评分(GPS)2、血浆纤维蛋白原(FIB)≥400 mg/dL为PFS和OS较差的的独立预测因素;小野寺预后营养指数(OPNI)是CRT后肿瘤减少率提高的预测因子(P<0.05);GPS 2、FIB≥400 mg/dL的患者的早期转移发生率显著提高(P<0.05)。结论:格拉斯哥预后评分、纤维蛋白原、小野寺预后营养指数是评估接受放化疗治疗的局部晚期胰腺癌患者有效的治疗和预后预测因子。
OBJECTIVE: To assess the predictive value of inflammation score for progression-free survival (PFS) and overall survival (OS) in locally advanced pancreatic cancer receiving radiochemotherapy (CRT). Methods: A total of 235 patients with advanced pancreatic cancer were enrolled. Before treatment, all patients underwent clinical assessment, laboratory examination and imaging examination. PFS and OS were compared between the two groups; the prognostic factors associated with poor prognosis, tumor reduction, and tumor metastasis within 6 months were assessed. Results: The mean PFS and OS were 10.2 months and 18.8 months respectively. Glasgow prognostic score (GPS) 2, fibrinogen (FIB) ≥ 400 mg / dL were independent predictors of poorer PFS and OS; OPNI was a predictor of tumor reduction after CRT P <0.05). The incidence of early metastasis was significantly increased in patients with GPS 2 and FIB≥400 mg / dL (P <0.05). CONCLUSION: The Glasgow prognostic score, fibrinogen, and Onoji prognostic trophic index are effective predictors of treatment and prognosis in locally advanced pancreatic cancer treated with chemoradiation.